secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0001178913-23-002136
Event type: leadership
Sentiment:  positive
Materiality: 0.80
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab appoints Adi Mor CEO, Sigal Fattal CFO; extends cash runway to end of 2024
--------------------------------------------------------------------------------

- Adi Mor, co-founder and CSO, reappointed CEO effective June 1, 2023, replacing Dale Pfost.
- Sigal Fattal, VP Finance, reappointed CFO, replacing Donald Marvin, effective same date.
- Nissim Darvish appointed Chairman of Board, replacing Pfost.
- Cash runway extended to end of 2024 via cost reductions; Phase 2 SSc trial suspended to preserve capital.
- On track for PSC Phase 2 topline data readout in latter part of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891323002136/0001178913-23-002136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891323002136/zk2329839.htm
  HTML page:      https://secwatch.observer/filing/0001178913-23-002136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer